ACC 2024: Sodium-Glucose Cotransporter 2 Inhibitors Safe, Effective in Adults With Congenital Heart Disease
Hospitalization rate for heart failure decreased significantly in the six months after SGLT2i initiation versus six months before
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.